Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | AHCY | P23526 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5493631 | 0.88 | EHMT1 (0.39) | EHMT1BCHEAHCYRXFP1ADORA2A | |
| SCHEMBL6239243 | 0.79 | BCHE (0.53) | BCHEAHCYADORA2A | |
| SCHEMBL9218734 | 0.79 | BCHE (0.51) | BCHEAHCYADORA2A | |
| SCHEMBL9231760 | 0.78 | EHMT1 (0.76) | EHMT1AHCYRXFP1ADORA2A | |
| SCHEMBL1637468 | 0.78 | EHMT1 (0.76) | EHMT1AHCYRXFP1ADORA2A | |
| SCHEMBL11489328 | 0.78 | EHMT1 (0.58) | EHMT1AHCYRXFP1ADORA2A | |
| SCHEMBL112551 | 0.77 | ADORA3 (0.57) | AHCYADORA2A | |
| SCHEMBL1980312 | 0.77 | ADORA3 (0.57) | AHCYADORA2A | |
| SCHEMBL7153500 | 0.77 | ADORA3 (0.57) | AHCYADORA2A | |
| SCHEMBL1920531 | 0.77 | EHMT1 (0.74) | EHMT1AHCYRXFP1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654270-B1 | PROCESS FOR PREPARING 2',3'-DIDEHYDRO-2',3'-DIDEOXYNUCLEOSIDES AND 2',3'-DIDEOXYNUCLEOSIDES | ARCHIMICA SRL (IT) | 2007-12-26 | — | — | EP | disclosed |
| US-20060199959-A1 | Process for preparing 2',3'-didehydro-2'3'-dideoxynucleosides and 2',3'-dideoxynucleosides | ARCHIMICA S.R.L. (IT) | 2006-09-07 | — | — | US | disclosed |
| EP-1654270-A1 | PROCESS FOR PREPARING 2',3'-DIDEHYDRO-2',3'-DIDEOXYNUCLEOSIDES AND 2',3'-DIDEOXYNUCLEOSIDES | Clariant Life Science Molecules (Italia) S.p.A. (IT) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005012325-A1 | PROCESS FOR PREPARING 2',3'-DIDEHYDRO-2',3'-DIDEOXYNUCLEOSIDES AND 2',3'-DIDEOXYNUCLEOSIDES | CLARIANT LIFE SCIENCE MOLECULES (ITALIA) S.P.A. (IT) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199959-A1 | Process for preparing 2',3'-didehydro-2'3'-dideoxynucleosides and 2',3'-dideoxynucleosides | DOHH, UMPS, DCPS | EHMT1 3758/4885BCHE 1098/4885AHCY 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.